A causative role for adiponectin in asthma has been established in mice. However, in the absence of longitudinal studies, the adiponectin-asthma association is not established in humans.
WHAT THIS STUDY ADDS TO THE FIELD
In this longitudinal cohort, we demonstrate that low serum adiponectin concentrations, independent of obesity, predict higher risk for incident asthma among middle-aged women, particularly among current smokers. Measures that raise systemic adiponectin concentrations may lead to newer ways to prevent asthma among women and particularly those who smoke. In 2005, more than 21 million people in the United States were estimated to be affected by asthma, amounting to 7.6% of the total population (1). Between 1980 and 1996, the prevalence of, and morbidity trends related to asthma increased in the United States (2, 3) . It is now well-established that asthma is related to adiposity, particularly among women. Adipokines, proteins produced by adipose tissue, may regulate systemic inflammation and play a role in asthma (4) (5) (6) (7) . Adiponectin is one such adipokine with predominantly anti-inflammatory effects. Adiponectin inhibits pro-inflammatory cytokines and endothelial adhesion molecules and induces anti-inflammatory cytokines (8) (9) (10) (11) .
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Further, adiponectin regulates the proliferation and function of inflammatory cells including NK-cells and T-lymphocytes (12, 13) .
Although visceral adipocytes are the most important source of adiponectin, serum adiponectin concentrations are reduced in obese subjects (14, 15) . One possible explanation is that hypoxia-related necrosis of adipocytes activates macrophages in obese subjects (16) . These activated macrophages produce tumor necrosis factoralpha (TNFα) and interleukin (IL)-6 which in turn may directly inhibit the local production of adiponectin in a paracrine fashion (17) . Adiponectin and all of the known receptors for adiponectin (AdipoR1, AdipoR2, T-cadherin, and calreticulin) are expressed on multiple cell types in the lung (18) (19) (20) . Adiponectin is also transported (20, 21) .
A causative role for adiponectin in asthma has been better established in mice than in humans (22) . Murine studies have however shown that this association is bidirectional, whereby exogenous adiponectin attenuates airway changes of asthma and allergeninduced bronchoprovocation decreases adiponectin concentrations (22) . Although current human data remain inconclusive, our previous cross-sectional study shows that low serum adiponectin concentrations are associated with increased odds for prevalent asthma among women and not men (6) . The direction of the adiponectin-asthma association in women is however not established. In other words, it is not known if low serum adiponectin predicts future risk for asthma or if presence of asthma lowers subsequent serum adiponectin concentrations among women. Our objective was to determine the longitudinal associations between serum adiponectin and incident asthma among women. If systemic adiponectin affects risk for incident asthma, measures that modify systemic adiponectin concentrations may lead to new preventive strategies for adult-onset asthma among women. years later. Retention of CARDIA participants has been excellent; as 3,950, 3,672 and 3,549 survivors were respectively examined at years 10, 15 and 20 examinations, constituting 78%, 74% and 72% respectively from the baseline cohort. Self-reported information from subjects was obtained by trained interviewers using standardized questionnaires. Detailed methods, instruments, and quality control procedures are described at the CARDIA website (http://www.cardia.dopm.uab.edu/ex_mt.htm) and in other published reports (23, 24) .
Our primary analysis evaluated the association of serum adiponectin concentration at CARDIA year 15 examination with new cases of asthma (i.e. incident disease) among women at year 20 examination. Our secondary analysis evaluated the converse 
Inclusion and exclusion criteria:
The primary analysis included all women participants without prevalent asthma (as defined below) at CARDIA year 15 examination (n = 1,450). The flowchart of subject inclusion and exclusion is depicted in Figure E1 in the Online Data Supplement. The secondary analysis included 1,455 women participants at year 10 examination. To examine the longitudinal effect of asthma on serum adiponectin concentrations, cases of asthma newly diagnosed at year 15 examination were excluded from the secondary analysis. Those with missing data for independent variables and covariates were excluded from all analyses.
Independent and Dependent variables:
Morning blood samples were collected after at least 8 hours of fasting at CARDIA year 15 examination from seated participants with tourniquet use limited to 2 minutes to prevent hemoconcentration. Samples were then centrifuged, aliquoted, and frozen at −70°C within 90 minutes of the collection. Total adiponectin was measured in serum as part of the YALTA ancillary study by radioimmunoassay technique at Linco Research, Inc. (St. Charles, MO) using a rabbit polyclonal antibody and purified recombinant adiponectin standards with an effective range of 0.2 to 40 mg/L (25) . Correlation between adiponectin concentrations measured in 407 paired serum samples in a Asthma was defined by a self-reported provider diagnosis in the presence of either asthma symptoms in the year preceding the examination or verified use of asthma medications at the time of examination. Incident asthma, the primary dependent variable, was defined by the new occurrence of asthma at year 20 examination. The time axis for the measurement of the dependent and independent variables in the primary and secondary analyses in the study are depicted in Figure 1 .
Covariates:
Covariates included age, race, body mass index (BMI), current smoking, history of diabetes, logarithmically-transformed insulin resistance (defined by the homeostasis model assessment or HOMA) (26, 27) , and logarithmically-transformed physical activity score (based upon the questionnaire-assessed physical activity history score (28, 29) ) at year 15 examination; as well as self-report of hay fever, a surrogate marker of atopy (obtained at year 0 examination). The above listed covariates were selected since they have been shown to affect either asthma status or serum adiponectin concentration (14, 30 
RESULTS

Demographic characteristics:
The primary analysis included 1,450 women including 1,011 pre-menopausal women with 54 and 32 cases of incident asthma respectively at CARDIA year 20 examination.
Women with incident asthma at CARDIA year 20 examination had significantly lower annual household income and higher rates of current smoking at CARDIA year 15 examination than women without (Table I ). The two groups however did not differ with respect to BMI at year 15 examination, change in BMI between years 15 and 20 examinations or past history of hayfever. Further, the characteristics of incident asthma cases in Table I for pre-menopausal women were similar to those for all women.
Low serum adiponectin at year 15 predicted increased risk for incident asthma in women at year 20:
Women with incident asthma at CARDIA year 20 examination had significantly lower mean serum adiponectin concentrations at year 15 examination than women without incident asthma (Table I) However, the interaction between either menopausal status or atopic status and low serum adiponectin (among all women) on risk for incident asthma was not significant (Table II) . Details of additional non-significant interactions are provided in the Online Data Supplement.
On the other hand, there was a significant interaction between current smoking and low serum adiponectin concentrations at year 15 examination on incident asthma among all women (unadjusted p=0.04; adjusted p=0.051) and among premenopausal women (unadjusted p=0.03; adjusted p=0.048). In other words, low serum adiponectin was associated with higher risk for incident asthma among current smokers than former/never smokers, among both all women ( Figure 2 ) and premenopausal women.
Interestingly, BMI at CARDIA year 15 examination did not predict incident asthma among all women at year 20 examination (Table IV) . Change in BMI between years 15 and 20 examinations was not predictive either. Multivariable stepwise logistic regression analysis confirmed the relative importance of low serum adiponectin (p=0.048) over BMI (p=0.74) in predicting incident asthma among all women. Similar results were seen among female current smokers. Among female former/never smokers, we found that neither BMI nor adiponectin predicted incident asthma. Similar overall results were seen among premenopausal women.
Neither low serum adiponectin (studied as a categorical or a continuous variable) nor BMI predicted incident asthma in men, although sex-adiponectin and sex-BMI interactions on incident asthma did not reach statistical significance. In this longitudinal cohort, we demonstrate that low serum adiponectin concentrations, independent of BMI, predict higher risk for incident asthma among middle-aged women, particularly among current smokers. We also show that the converse relationship i.e. prevalent asthma predicting future serum adiponectin concentrations, is not true among women. Thus, the findings of our longitudinal study suggest a clear direction to our previously-described cross-sectional association between serum adiponectin and asthma among women (6) . Although serum adiponectin concentrations and BMI are inversely correlated with each other (r of -0.33; p < 0.001), we found that low values of the former may be more important than high values of the latter in predicting the risk for incident asthma among female current smokers.
The literature pertaining to the adiponectin-asthma association is conflicting and confusing. Five human studies have analyzed the association between serum adiponectin and odds of prevalent asthma, independent of obesity (6, (31) (32) (33) (34) , of which three studies show no significant associations (32) (33) (34) (Table E -III, Online Data Supplement). These studies are limited by their smaller numbers of girls/women, modest effect sizes, and lower prevalence of asthma and obesity in populations outside the United States (32) (33) (34) . The two positive studies, being cross-sectional in nature, are unable to establish the direction of the association (6, 31) . Interestingly, a short longitudinal study of adolescents with moderate-to-severe asthma showed that low baseline serum adiponectin concentrations were associated with worse disease control (22) . We had previously demonstrated in our small interventional study that acute bronchoprovocation by allergen inhalation did not affect serum adiponectin concentrations in sensitized human subjects with asthma (36) . Our current longitudinal study thus confirms a unidirectional inverse association of serum adiponectin to incident asthma among women. Based upon our findings, we hypothesize that measures that raise systemic adiponectin concentrations may help prevent asthma onset among women, particularly among those who smoke. On the other hand, it is possible that this strategy may not benefit men, in light of our previously published finding that systemic adiponectin is adversely associated with asthma outcomes in men (37) .
Compared to previous negative adiponectin-asthma studies (32) (33) (34) , we speculate that our study had greater statistical power due to both a planned selection of large numbers of blacks and a fortuitous selection of large numbers of obese subjects and smokers, groups known to be associated with lower serum adiponectin concentrations (14) . We further did not find a linear relationship between serum adiponectin and incident asthma, as seen on Figure E2 in the Online Data Supplement. Since the depicted relationship may show a threshold effect i.e. only seen with the lowest tertile of serum adiponectin concentration, it is important to have adequate numbers in this group for any study to demonstrate a significant effect on incident asthma. This may explain why our results may differ from previous negative studies in the field (32) (33) (34) . Further, we F o r R e v i e w O n l y demonstrate a greater asthma risk due to lower serum adiponectin concentrations among women who currently smoke than women who do not currently smoke but the mechanistic basis for this interaction is not currently known.
Although we showed an association between low serum adiponectin and asthma among women, the sex-specific interaction was not significant (p=0.24). In the absence of a sex-specific interaction, we cannot be certain that a similar effect is not seen among men. Our sex-specific analytic approach was primarily based upon our previously published finding of a sex-specific cross-sectional interaction of serum adiponectin on asthma outcomes in the same cohort (38) . It is likely that our power for the interaction analysis in the current study was limited by the fewer cases of incident asthma among our otherwise equivalently-sized sample of men (n=16/1,171). Further, we did not find that combining both sexes increased our power. It should also be noted that serum adiponectin displays marked sexual dimorphism in its isoform profiles (39, 40) .
Compared to men, women have higher concentrations of the high-molecular weight isoform (39, 40) . The latter isoform is also the dominant isoform in murine lung (21) and may be the most biologically relevant isoform. Our study however did not measure adiponectin isoforms.
Interestingly, obese mice show airway responsiveness but without high eosinophil counts or atopic (TH2) cytokine expression in the airway (41) . Leptin, another adipokine, stimulates lymphocytes towards a non-atopic (TH1) cytokine profile rather than an atopic (TH2) one (42) . In a small cross-sectional study of German children, serum adiponectin was more strongly associated with non-atopic prevalent asthma than with atopic prevalent asthma (no interaction term reported), using a self-reported measure of atopy (Table E-III in the Online Data Supplement (31) ). However, using a similar measure to define atopy, our findings suggest that the association between serum adiponectin and incident asthma among women does not vary by atopic status. Since the predictor status of atopy for incident asthma in longitudinal studies weakens during adulthood as compared to childhood (43) (44) (45) (46) , it is possible that atopy may cease to be an effect modifier for the adiponectin-asthma association during adulthood.
We were surprised to find that BMI did not predict incident asthma in our analyses.
These findings were thus contrary to our previous findings from the same cohort that demonstrated that baseline BMI and change in BMI predicted incident asthma in women between years 0 and 10 examinations (47) . The absolute gain in BMI in kg/m 2 for women between years 0 and 10 examination visits is 3.04 ± 3.64 (SD); between years 10 and 15 is 1.44 ± 2.78; and between years 15 and 20 is 0.86 ± 3.01. Thus, the decline in rate of gain in body mass with increasing age may make BMI at year 15 and the change in BMI between years 15 and 20 less predictive for incident asthma in women at year 20 than was the case during the earlier period between years 0 and 10. Further, it is also possible that obesity is a stronger predictor for incident asthma in younger (more sex hormonally active) women than in middle-aged women. Finally, while the previous analysis looked at accumulated incident asthma over years 2, 7 and 10 examinations The strengths of our study include its focus on women, well-defined study population set within a cohort structure, and its clinical translational character, based on the recently published data on the role of systemic adiponectin in mouse and human asthma (6, 22, 38) . Further, the results from our longitudinal analyses are supported by our previous cross-sectional analyses (6) .
The study however, has some limitations. Selection bias may occur if those measured for serum adiponectin were not representative of the CARDIA study population.
However, our ad-hoc analysis did not demonstrate that those measured were different from those not measured with respect to both obesity and asthma. Use of self-reported asthma diagnosis may result in misclassification. However, this misclassification bias is likely non-differential (48) . In addition, self-report may miss subjects with mild asthma.
However, this is unlikely, given that most subjects with asthma in our study were of intermittent or mild persistent severity (49). In addition, self-reported asthma may include early chronic obstructive pulmonary disease, particularly among smokers.
However, this seems less likely since most women with incident asthma in our study had normal FEV 1 /FVC ratio (Table I) . On the other hand, we cannot rule out the possibility of chronic bronchitis being misdiagnosed as asthma in our study. However, that error is likely to cause a non-differential misclassification bias and is unlikely to produce a spurious result. Further, in order to confirm definitively that adiponectin has a different effect on asthma status between men and women, a statistically significant interaction is required. Our analysis may lack the statistical power to significantly detect this interaction. This study did not separately measure various serum adiponectin isoforms that may have varying in vivo activity in asthma. Interestingly, a recent study showed no significant correlation between airway and systemic concentrations of total adiponectin; the various isoforms were however not compared (50) . Further, our definition of atopy was limited to self-reported hayfever at CARDIA year 0 examination and was not confirmed by objective tests. Finally, adiponectin measurements were not repeated at other examination visits. A single assessment of a biomarker may be susceptible to short-term variation and may not reflect long-term exposure. However, studies suggest that serum concentrations of adiponectin are stable and therefore serum adiponectin is a good candidate for long-term epidemiologic risk assessment (51) (52) (53) .
In summary, our longitudinal study demonstrates that low serum adiponectin predicts future risk for incident asthma among middle-aged women and not vice versa.
Measures that raise systemic adiponectin concentrations may lead to newer ways to prevent asthma among women and particularly among those who smoke. The two-way interaction for the adjusted analysis between current smoking status and low serum adiponectin category on incident asthma, as reflected in this table, was significant among premenopausal women (p = 0.048) and tended towards significance among all women (p = 0.051) but was not significant among men. The three-way interaction between sex, current smoking status and low serum adiponectin category on incident asthma was not significant. Note 6: Other Interactions: The interaction between sex and low serum adiponectin category on incident asthma among all subjects was not significant. Similar non-significant interactions were noted on incident asthma among women between low serum adiponectin category and either of the following variables -race; BMI; atopy; insulin resistance; physical activity; and menopause. Details are provided in the Online Data Supplement. Key: BMI: body mass index 
Primary analyses -Interaction effects
Three-way interactions: The three-way interaction for the adjusted analyses between low serum adiponectin category, obese status, and current smoking status on incident asthma among women did not reach statistical significance, possibly due to the small number of cases (adjusted p=0.28). In other words, obese women may not show a greater susceptibility to the effects of smoking on increased asthma risk due to lower serum adiponectin concentrations than non-obese women.
Similarly, the three-way interaction for the adjusted analyses between sex, current smoking status and low serum adiponectin category on incident asthma was not significant (p = 0.18). In other words, women may not show a greater susceptibility to the effects of smoking on increased asthma risk due to lower serum adiponectin concentrations than men.
Further, the three-way interaction for the adjusted analyses between menopausal status, current smoking status, and low serum adiponectin category on incident asthma among women was not significant (p = 0.96). In other words, premenopausal women may not show a greater susceptibility to the effects of smoking on increased asthma risk due to lower serum adiponectin concentrations than postmenopausal women. 
Two-way interactions:
We present additional data for multiple two-way statistical interactions in our study.
Smoking interaction:
The two-way interaction for the adjusted analysis between current smoking status and low serum adiponectin category on incident asthma, as reflected in Table II in the main text, was significant among premenopausal women (p = 0.048) and
tended towards significance among all women (p = 0.051; this data is also visually depicted in Figure 2 in the main text). However, this interaction was not significant among men (p = 0.57).
Sex interaction:
The two-way interaction for the adjusted analysis between sex and low serum adiponectin category on incident asthma among all subjects (70/2,621) was also not significant (p=0.24). Since we did not find a significant interaction between sex and low serum adiponectin on incident asthma, one strategy was to present the results for all subjects. When we did that, we found no significant association between low serum adiponectin category and incident asthma (p=0.39). On the other hand, in models adjusting for sex and standard covariates, we found such an association (p=0.048). We found that sex was a significant confounder in this association and that combining both sexes did not increase our power. On the other hand, we lost power to detect a significant interaction between current smoking and low serum adiponectin on incident asthma (p=0.15). For reasons mentioned in the main text, we believe that stratifying results by sex is reasonable as well as consistent with our prior studies (E1, E2). Note 1: Incident asthma and menopausal status were measured at CARDIA year 20 examination. Note 2: The adjusted models included age, race, BMI, current smoking, history of diabetes, logarithmicallytransformed insulin resistance, and logarithmically-transformed physical activity score (at year 15 examination) and history of hayfever (at year 0 examination). Note 3: Similar associations as above were noted in Table II in the main text for categorical adiponectin predictor variables. The odds ratios for the logarithmically transformed continuous variables have been inverted to represent low serum adiponectin values and to match the direction of association reported in the main text. 78.0±8.5 78.2±6.3 * Comparison between asthma and controls significant at p value < 0.05. Note 1: Incident asthma was measured at CARDIA year 20 examination; all other data are measured at CARDIA year 15 examination, unless otherwise indicated. Data are presented as mean ± SD. Geometrical mean is presented with 95% C.I. in parentheses. Note 2: Distribution of selected characteristics among women with incident asthma (at CARDIA year 20 examination) and controls is presented in Table 1 in the main text. 
